Eli Lilly Profile

85.73
USD 0.33  0.38%
84.65Last Month High 87.65 
85.52Trading Day  High 86.56 

Acquisition by Juan Luciano of 112 shares of Eli Lilly subject to Rule 16b-3

Eli Lilly and Company insider trading alert for grant of common stock by Juan Luciano, the corporate stakeholder, on October 18, 2017. This event was filed by Lilly Eli Co with SEC on 2017-10-18. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Eli Lilly Summary

If you have read previous articles here on Macroaxis, then you will likely know that pharmaceutical stocks or any drug creating stocks can be volatile, with today proving that point. When the FDA decides to reject a product, it essentially costs the company hundreds of millions of dollars because they put so much time and energy into research and development, as well as experimentations. So when that happens, you can see a stock drop dramatically out of the sky, causing long term investors to worry because they are not looking for the volatility. [more]
Eli Lilly and Company (LLY) is traded on New York Stock Exchange in USA. It is located in INDIANA, U.S.A and employs 41,275 people. Eli Lilly is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Large-Cap' category with total capitalization of 90.63 B. Eli Lilly and Company runs under Healthcare sector within Pharmaceuticals And Biosciences industry. This company has 1.05 B outstanding shares of which 10.18 M shares are now shorted by investors with about 2.62 days to cover shorted positions. LILLY ELI CO has about 5.44 B in cash with 5.66 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.15.
Check Eli Lilly Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Eli Lilly and Company Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Eli Lilly Against Markets

Risk Adjusted
Performance Score (0 to 100)
23 
Chance of
< 11% 
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical solutions worldwide. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameEli Lilly and Company
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Bond Rating
Specialization
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationINDIANA, U.S.A
Business AddressLilly Corporate Center, Indianapolis, IN 46285, United States
Foreign Associates
ExchangeNew York Stock Exchange
CIK Number00059478.0
ISINUS5324571083
CUSIP532457108
SectorHealthcare
IndustryPharmaceuticals And Biosciences
BenchmarkDOW
Websitewww.lilly.com
Contact Number317 276 2000
CurrencyUSD - US Dollar

Current Sentiment - LLY

Eli Lilly and Investor Sentiment
Predominant part of Macroaxis users are now bullish on Eli Lilly and Company. What is your opinion about investing in Eli Lilly and Company? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Eli LillySkip  Hide

Recommendations

Eli Lilly Analyst Recommendations
Target PriceAdvice# of Analysts
84.6Buy15Odds
Eli Lilly and Company current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Eli Lilly Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Eli Lilly Earnings Estimates
EPSEstimate Date
Quarterly Estimate0.94April 25, 2017
Eli Lilly and Company normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate